Total Funding
9
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
246386
Argos Therapeutics develops immunotherapy treatments for cancers, infectious and autoimmune diseases, and transplantation rejection.
Acquired by 
SCM Lifescience
Charles A. Nicolette: Chief Scientific Officer and VP, Research and DevelopmentPast Role: Genzyme, Director of Antigen Discovery- Doug Plessinger: Vice President, Clinical and Medical AffairsPast Role: Bristol-Myers Squibb, Various Roles of Increasing Responsibility
About the Company
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83
soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
